Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer

Journal of Clinical Oncology

Volumn 28, Issue 15, 2010, Pages 2598-2603

  Ettinger, David S ^a   Jotte, Robert ^a   Lorigan, Paul ^a   Gupta, Vicram ^a   Garbo, Lawrence ^a   Alemany, Carlos ^a   Conkling, Paul ^a   Spigel, David R ^a   Dudek, Arkadiusz Z ^a   Shah, Chirag ^a   Salgia, Ravi ^a   McNally, Richard ^a   Renschler, Markus F ^a   Oliver, Jennifer W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMRUBICIN; PLATINUM; ANTHRACYCLINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; DEHYDRATION; DRUG ACTIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RESPIRATORY TRACT DISEASE; THORAX DISEASE; THROMBOCYTOPENIA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMALL CELL LUNG CARCINOMA; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77956396425     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.7682     Document Type: Article

References (27)

1. Witta SE, Kelly K: Chemotherapy for small cell lung cancer, in Pass HI, Mitchell JB, Johnson DH, et al (ed): Lung Cancer: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, 2005, pp 657-674
2. Jackman DM, Johnson BE: Small-cell lung cancer. Lancet 366:1385-1396, 2005 (Pubitemid 41443406)
3. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006 (Pubitemid 46630948)
4. Giaccone G, Donadio M, Bonardi G, et al: Teniposide in the treatment of small-cell lung cancer: The influence of prior chemotherapy. J Clin Oncol 6:1264-1270, 1988
5. Ardizzoni A, Hansen H, Dombernowsky P, et al: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease-The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15:2090-2096, 1997
6. O'Brien ME, Ciuleanu TE, Tsekov H, et al: Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24: 5441-5447, 2006 (Pubitemid 46623178)
7. Onoda S, Masuda N, Seto T, et al: Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 24:5448-5453, 2006 (Pubitemid 46623179)
8. Eckardt JR, von Pawel J, Pujol JL, et al: Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 25:2086-2092, 2007 (Pubitemid 46972795)
9. von Pawel J, Gatzemeier U, Pujol JL, et al: Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19:1743-1749, 2001 (Pubitemid 32230876)
10. Hycamtin US Prescribing Information. http://us.gsk.com/products/assets/ us-hycamtin.pdf
11. Hycamtin Summary of Product Characteristics (EU). http://www.emea.europa. eu/humandocs/PDF/EPAR/Hycamtin/H-123-PI-en.pdf
12. Park SH, Cho EK, Kim Y, et al: Salvage treatment with topotecan in patients with irinotecanrefractory small cell lung cancer. Cancer Chemother Pharmacol 62:1009-1014, 2008
13. Perez-Soler R, Glisson BS, Lee JS, et al: Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14:2785-2790, 1996 (Pubitemid 26329665)
14. Inoue K, Ogawa M, Horikoshi N, et al: Phase I and pharmacokinetic study of SM-5887, a new anthracycline derivative. Invest New Drugs 7:213-218, 1989 (Pubitemid 19202362)
15. Yamaoka T, Hanada M, Ichii S, et al: Cytotoxicity of amrubicin, a novel 9-aminoanthracycline, and its active metabolite amrubicinol on human tumor cells. Jpn J Cancer Res 89:1067-1073, 1998 (Pubitemid 28544784)
16. Hanada M, Mizuno S, Fukushima A, et al: A new antitumor agent amrubicin induces cell growth inhibition by stabilizing topoisomerase II-DNA complex. Jpn J Cancer Res 89:1229-1238, 1998 (Pubitemid 29008005)
17. Luna-Moran A, Aukerman L, Heise C, et al: Amrubicin, a third generation anthracycline, inhibits growth of human breast cancer cell lines and primary tumor explants. Presented at the 100th Annual Meeting of the Am Assoc Cancer Res, Denver, CO, April 18-22, 2009 (abstr 880)
18. Noda T, Watanabe T, Kohda A, et al: Chronic effects of a novel synthetic anthracycline derivative (SM-5887) on normal heart and doxorubicin-induced cardiomyopathy in beagle dogs. Invest New Drugs 16:121-128, 1998 (Pubitemid 28495213)
19. Hasegawa Y, Takanashi S, Okudera K, et al: Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med 44:26-34, 2005 (Pubitemid 40260037)
20. Kato T, Nokihara H, Ohe Y, et al: Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol 24:379sg, 2006 (suppl; abstr 7061)
21. Inoue A, Sugawara S, Yamazaki K, et al: Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated smallcell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 26:5401-5406, 2008
22. Ettinger DS: Amrubicin for the treatment of small cell lung cancer: Does effectiveness cross the Pacific? J Thorac Oncol 2:160-165, 2007
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
24. Fleming TR: One-sample multiple testing procedure for phase II clinical trials. Biometrics 38:143-151, 1982
25. von Pawel J, Schiller JH, Shepherd FA, et al: Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent smallcell lung cancer. J Clin Oncol 17:658-667, 1999 (Pubitemid 29075255)
26. Eckardt JR, Bentsion DL, Lipatov ON, et al: Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol 27:2046-2051, 2009
27. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006